Theriva Biologics anuncia la designación de fármaco huérfano concedida por la FDA estadounidense al VCN-01 para el tratamiento del cáncer de páncreas
Theriva Biologics, a clinical-stage biotechnology company focused on developing therapies for cancer and related diseases in underserved areas, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its lead clinical candidate, VCN-01, for the treatment of pancreatic cancer. Pancreatic ductal adenocarcinoma (PDAC) has one of the lowest survival rates among all cancers, and








